Stem Cell Ophthalmology Treatment Study II

Other

• Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.
• Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.
• Patients who are not capable of providing informed consent.
• Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.

• Have objective, documented damage to the retina or optic nerve unlikely to improve OR
• Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20/30 best corrected central visual acuity in one or both eyes AND/OR an abnormal visual field in one or both eyes.
• Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.
• If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).
• Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.
• Be over the age of 18
• Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.
• Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.